Combination chemotherapy with etoposide, leucovorin and 5-FU (ELF) was investigated in a phase-II study in patients with advanced gastric carcinoma (stage III and IV). Only ambulatory patients (performance status WHO ≤2) above 65 years or younger patients with cardiac disease were entered. A remission rate of 53% could be achieved in 51 evaluable patients, including 12% complete remissions. One toxic death was observed. Remission rate was particularly high in patients with locally advanced disease (70%, 7/10 patients). Median remission duration was 8 months, median overall survival 11.5 months. Patients with peritoneal carcinosis lived significantly shorter than those with other distant metastases (P < 0.05). ELF was well tolerable. The efficacy of ELF, combined with its moderate toxicity, make this therapy a useful approach in the treatment of gastric cancer, where treatment intention is palliative so far.
No takes yet. Share an insight, caveat, or question.
Stahl et al. (2009) studied this question.